The study results indicate bioequivalent pharmacokinetics between ANX-514 and the FDA-approved version of Taxotere. Furthermore, ANX-514, administered intravenously, did not cause hypersensitivity reactions in this study, as opposed to acute hypersensivity reactions observed following intravenous treatment with Taxotere. Taxotere is an agent used for the treatment of breast, non-small cell lung, prostate and gastric cancers.
“These results suggest that treatment with ANX-514 may eliminate the need for multi-day premedication with corticosteroids prior to treatment, which is currently recommended prior to treatment with Taxotere,” said Evan Levine, CEO for Adventrx.
Adventrx is continuing to conduct additional preclinical pharmacokinetic testing of ANX-514 to compare this product candidate with Taxotere.